Your browser doesn't support javascript.
loading
Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients.
Gawaz, A; Wolff, I; Nanz, L; Flatz, L; Forschner, A.
Afiliação
  • Gawaz A; Universitätshautklinik Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Germany. andrea.gawaz@med.uni-tuebingen.de.
  • Wolff I; Universitätshautklinik Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Germany.
  • Nanz L; Universitätshautklinik Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Germany.
  • Flatz L; Universitätshautklinik Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Germany.
  • Forschner A; Universitätshautklinik Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Germany.
Cancer Immunol Immunother ; 73(9): 185, 2024 Jul 05.
Article em En | MEDLINE | ID: mdl-38969911
ABSTRACT

BACKGROUND:

Immune checkpoint inhibitors (ICI) applied in patients with melanoma in an adjuvant setting have proven safety and efficacy in several studies, but data on elderly patients aged 75 years or more is scarce. Aim of this study was to investigate efficacy and safety of adjuvant ICI in patients aged ≥ 75 years compared to patients < 75 years in a real-world setting.

METHODS:

We retrospectively analyzed clinical data, including occurrence of immune-related adverse events (irAE) and outcome of 456 patients that had been treated with adjuvant ICI between January 1st, 2018 and December 20th, 2022. We then compared patients aged ≥ 75 years (n = 117) to patients < 75 years (n = 339) in terms of safety and disease-free survival (DFS). RESULTS AND

CONCLUSION:

ICI were well tolerated in both groups, with no significant difference observed in the overall occurrence of irAE. However, within the elderly subgroup, there was a significantly higher proportion of skin or nephrological toxicity and colitis/diarrhea compared to the other group. In terms of efficacy, a significantly shorter DFS in patients aged ≥ 75 years was observed. Adjuvant ICI in patients ≥ 75 years was less effective and furthermore associated with an increased risk for skin, renal or bowel toxicity. Therefore, in elderly patients, adjuvant ICI should be used with precaution.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Nivolumabe / Inibidores de Checkpoint Imunológico / Melanoma Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Immunol Immunother Assunto da revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Nivolumabe / Inibidores de Checkpoint Imunológico / Melanoma Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Immunol Immunother Assunto da revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha